HCPCS (Healthcare Common Procedure Coding System) codes are essential for medical billing, ensuring accurate reimbursement for drugs, supplies, and procedures. Among these, HCPCS Code J9144 represents a critical medication in oncology—daratumumab (Darzalex). This injectable drug is primarily used to treat multiple myeloma, a type of blood cancer affecting plasma cells.
With the rising prevalence of multiple myeloma and advancements in immunotherapy, understanding J9144 is crucial for healthcare providers, coders, and billing specialists. This article provides an in-depth exploration of HCPCS Code J9144, covering its clinical use, billing guidelines, reimbursement policies, and future developments.
HCPCS Code J9144
2. Understanding HCPCS Code J9144
Definition and Purpose
HCPCS Code J9144 is designated for daratumumab (Darzalex), a monoclonal antibody used in cancer therapy. The code applies to per-milligram billing, allowing precise claims for administered doses.
Drug Classification
Daratumumab falls under the CD38-directed cytolytic antibody class, targeting cancer cells while sparing healthy tissues.
Key Details of HCPCS Code J9144
| Parameter | Details |
|---|---|
| HCPCS Code | J9144 |
| Drug Name | Daratumumab (Darzalex) |
| Administration Route | Intravenous (IV) or Subcutaneous (SC) |
| FDA Approval Year | 2015 (IV), 2020 (SC) |
| Therapeutic Class | Monoclonal Antibody |
3. Drugs Covered Under J9144
Daratumumab (Darzalex) Overview
Developed by Janssen Pharmaceuticals, daratumumab binds to CD38 proteins on myeloma cells, triggering immune-mediated destruction.
Mechanism of Action
-
Antibody-Dependent Cellular Cytotoxicity (ADCC)
-
Complement-Dependent Cytotoxicity (CDC)
-
Apoptosis Induction
FDA Approval and Indications
-
Relapsed/Refractory Multiple Myeloma
-
Newly Diagnosed Multiple Myeloma (in combination therapies)
Common Daratumumab Combination Regimens
| Regimen | Usage |
|---|---|
| Darzalex + Lenalidomide + Dexamethasone (DRd) | First-line therapy |
| Darzalex + Bortezomib + Dexamethasone (DVd) | Relapsed cases |
| Darzalex + Pomalidomide + Dexamethasone (DPd) | Advanced myeloma |
4. Coding and Billing Guidelines
Proper Usage of J9144
-
1 mg = 1 unit (e.g., 400 mg dose = 400 units billed).
-
Must include diagnosis codes (e.g., C90.00 for multiple myeloma).
Documentation Requirements
-
Medical necessity justification.
-
Dosage records and administration notes.
5. Reimbursement and Coverage Policies
-
Medicare Part B covers J9144 under medical benefit.
-
Prior authorization often required by private insurers.
6. Clinical Applications
-
Significant progression-free survival improvement.
-
Subcutaneous formulation reduces infusion reactions.
7. Side Effects and Safety Considerations
-
Common: Fatigue, neutropenia, respiratory infections.
-
Severe (rare): Infusion-related reactions, cardiac issues.
8. Comparative Analysis with Similar Drugs
-
More effective than bortezomib in some studies.
-
Higher cost but better long-term outcomes.
9. Future Developments and Research
-
Ongoing trials for amyloidosis and other cancers.
-
Biosimilars in development.
10. Conclusion
HCPCS Code J9144 (daratumumab) is vital in multiple myeloma treatment, offering improved survival rates. Proper billing, documentation, and adherence to guidelines ensure optimal reimbursement. Ongoing research promises expanded applications, reinforcing its role in oncology.
11. FAQs
Q1: What is HCPCS Code J9144 used for?
A: It bills for daratumumab (Darzalex), a multiple myeloma treatment.
Q2: How is J9144 billed?
A: Per milligram (1 mg = 1 unit) with appropriate ICD-10 codes.
Q3: Does Medicare cover J9144?
A: Yes, under Part B with medical necessity.
